"Oncology Biosimilars Market – Industry Trends and Forecast to 2029
Global Oncology Biosimilars Market, By Indication (Breast Cancer, Lung Cancer, Colorectal Cancer, Cervical Cancer, Blood Cancer, Others), Drug Class (Monoclonal Antibodies, Granulocyte Colony-Stimulating Factor, Others), Route of Administration (Intravenous, Subcutaneous, Others), End-Users (Hospitals, Specialty Clinics, Homecare, Others), Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy, Others) – Industry Trends and Forecast to 2029
Data Bridge Market Research analyses that the oncology biosimilars market was valued at USD 4.00 billion in 2021 and is expected to reach USD 15.55 billion by 2029, registering a CAGR of 18.5% during the forecast period of 2022 to 2029. In addition to the market insights such as market value, growth rate, market segments, geographical coverage, market players, and market scenario, the market report curated by the Data Bridge Market Research team also includes in-depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.
Access Full 350 Pages PDF Report @
https://www.databridgemarketresearch.com/reports/global-oncology-biosimilars-market
A biosimilar is a generic counterpart of a well-known biologic medicine. Medications made from living substances such as cells, tissues, or proteins are known as biologic drugs. A biosimilar is a medication that is based on a biologic drug that has already been studied, produced, clinically tested for safety and effectiveness, and authorized by the US Food and Drug Administration (FDA). Since the biosimilar is based on the approved drug, the biologic medications are commonly referred to as reference drugs. The functions of biosimilar are same as the reference drugs and it is dependent to FDA approval.
**Segments**
- By Product Type: Based on product type, the oncology biosimilars market can be segmented into monoclonal antibodies, immunomodulators, and supportive cancer care biosimilars. Monoclonal antibodies hold a significant share in the market as they are widely used in the treatment of various cancers. Immunomodulators, on the other hand, are also gaining traction due to their ability to regulate the immune system to fight cancer. Supportive cancer care biosimilars include oncology biosimilars used for managing side effects of cancer treatment.
- By Indication: The indication segment categorizes the market based on the type of cancer the biosimilars are used to treat. Some common indications include breast cancer, colorectal cancer, lung cancer, leukemia, lymphoma, and others. The demand for oncology biosimilars varies across these indications, with established biosimilars for certain types of cancer and emerging opportunities in others.
- By Distribution Channel: Distribution channels for oncology biosimilars include hospital pharmacies, retail pharmacies, online pharmacies, and others. Hospital pharmacies play a crucial role in the distribution of oncology biosimilars due to the specialized nature of cancer treatment. Retail pharmacies are also significant, providing accessibility and convenience to patients.
**Market Players**
- Pfizer Inc.
- Sandoz International GmbH
- Biocon
- Mylan N.V.
- Celltrion Inc.
- Dr. Reddy's Laboratories Ltd.
- Amgen Inc.
- Teva Pharmaceutical Industries Ltd.
- Samsung Bioepis
- STADA Arzneimittel AG
The global oncology biosimilars market is highly competitive with a mix of large pharmaceutical companies and specialized biosimilar manufacturers. Companies like Pfizer, Sandoz, and Biocon have established themselves as key players in the market, leveraging their expertise in biosimilar development and distribution. Other players such as Mylan, Celltrion,The global oncology biosimilars market is expected to witness significant growth in the coming years due to the increasing prevalence of cancer worldwide and the cost-effectiveness of biosimilar drugs compared to their originator counterparts. The market is segmented based on product type, indication, and distribution channel, allowing for a more focused analysis of the dynamics shaping the industry. Monoclonal antibodies, immunomodulators, and supportive cancer care biosimilars are the primary product types driving market growth, with monoclonal antibodies holding a substantial share due to their widespread use in cancer treatment.
In terms of indication, the market is categorized based on the type of cancer being treated, ranging from breast cancer and colorectal cancer to lung cancer, leukemia, and lymphoma. Each indication presents unique opportunities and challenges for oncology biosimilar manufacturers, with established players capitalizing on well-known cancer types and emerging players seeking to capture market share in untapped segments. The demand for biosimilars across different indications is influenced by factors such as pricing, efficacy, and physician preference, making it essential for companies to tailor their strategies accordingly.
The distribution channel also plays a crucial role in the oncology biosimilars market, with hospital pharmacies, retail pharmacies, and online pharmacies serving as key avenues for product access. Hospital pharmacies, in particular, are vital for the distribution of oncology biosimilars due to the specialized nature of cancer treatment and the need for close monitoring by healthcare professionals. Retail pharmacies and online pharmacies provide additional channels for patients to access biosimilar drugs, offering convenience and accessibility for those undergoing cancer treatment.
Key market players in the global oncology biosimilars market include Pfizer Inc., Sandoz International GmbH, Biocon, Mylan N.V., Celltrion Inc., Dr. Reddy's Laboratories Ltd., Amgen Inc., Teva Pharmaceutical Industries Ltd., Samsung Bioepis, and STADA Arzneimittel AG. These companies bring a mix of expertise in**Global Oncology Biosimilars Market, By Indication (Breast Cancer, Lung Cancer, Colorectal Cancer, Cervical Cancer, Blood Cancer, Others), Drug Class (Monoclonal Antibodies, Granulocyte Colony-Stimulating Factor, Others), Route of Administration (Intravenous, Subcutaneous, Others), End-Users (Hospitals, Specialty Clinics, Homecare, Others), Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy, Others) – Industry Trends and Forecast to 2029**
The global oncology biosimilars market is expected to witness significant growth over the forecast period, driven by factors such as the rising incidence of cancer worldwide, the cost-effectiveness of biosimilar medications, and the increasing demand for accessible cancer treatment options. The market segmentation based on product type, indication, and distribution channel allows for a comprehensive analysis of the industry dynamics and identifies key growth opportunities for market players.
Monoclonal antibodies, immunomodulators, and supportive cancer care biosimilars are the primary product types driving market expansion. Monoclonal antibodies, in particular, hold a substantial market share due to their widespread use in cancer therapy across various cancer types. Immunomodulators are also gaining popularity for their role in regulating the immune system to combat cancer, while supportive cancer care biosimilars are essential for managing treatment-related side effects.
By indication, the market is categorized into different types of cancer, including
Oncology Biosimilars Key Benefits over Global Competitors:
- The report provides a qualitative and quantitative analysis of the Oncology Biosimilars Market trends, forecasts, and market size to determine new opportunities.
- Porter’s Five Forces analysis highlights the potency of buyers and suppliers to enable stakeholders to make strategic business decisions and determine the level of competition in the industry.
- Top impacting factors major investment pockets are highlighted in the research.
- The major countries in each region are analyzed and their revenue contribution is mentioned.
- The market player positioning segment provides an understanding of the current position of the market players active in the Personal Care Ingredients
Table of Contents: Oncology Biosimilars Market
1 Introduction
2 Global Oncology Biosimilars Market Segmentation
3 Executive Summary
4 Premium Insight
5 Market Overview
6 Oncology Biosimilars Market, by Product Type
7 Oncology Biosimilars Market, by Modality
8 Oncology Biosimilars Market, by Type
9 Oncology Biosimilars Market, by Mode
10 Oncology Biosimilars Market, by End User
12 Oncology Biosimilars Market, by Geography
12 Oncology Biosimilars Market, Company Landscape
13 Swot Analysis
14 Company Profiles
Critical Insights Related to the Keyword Included in the Report:
- Exclusive graphics and Illustrative Porter’s Five Forces analysis of some of the leading companies in this market
- Value chain analysis of prominent players in the market
- Current trends influencing the dynamics of this market across various geographies
- Recent mergers, acquisitions, collaborations, and partnerships
- Revenue growth of this industry over the forecast period
- Marketing strategy study and growth trends
- Growth-driven factor analysis
- Emerging recess segments and region-wise market
- An empirical evaluation of the curve of this market
- Ancient, Present, and Probable scope of the market from both prospect value and volume
Browse Trending Reports:
Topical Drug Market
Augmented Reality Market
Building Management System Market
Cnc Controller Market
Gps Tracking Device Market
Energy Harvesting System Market
Industry 4 0 Market
Moisture Analyzer Market
Implantable Drug Delivery Market
Vehicle Analytics Market
Coating Equipment Market
In Vitro Diagnostics Ivd Market
14d Machine Vision Market
Patient Registry Software Market
Composite Bearings Market
Subscriber Data Management Market
Digital Health Technologies Market
Mobile Device Management Market
Oxidative Stress Assay Market
Vaccine Adjuvants Market
Viral Inactivation Market
Sludge Treatment Chemicals Market
Glucose Sensors Market
Gastrointestinal Gi Stent Market
Soy Protein Market
About Data Bridge Market Research:
Data Bridge set forth itself as an unconventional and neoteric Market research and consulting firm with unparalleled level of resilience and integrated approaches. We are determined to unearth the best market opportunities and foster efficient information for your business to thrive in the market. Data Bridge endeavors to provide appropriate solutions to the complex business challenges and initiates an effortless decision-making process.
Contact Us:
Data Bridge Market Research
US: +1 614 591 3140
UK: +44 845 154 9652
APAC : +653 1251 975
